Shares of Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) have been assigned an average recommendation of “Buy” from the seven analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $16.50.
RNN has been the subject of several analyst reports. Seaport Global Securities reiterated a “buy” rating and set a $13.00 price objective on shares of Rexahn Pharmaceuticals in a report on Friday, October 6th. Zacks Investment Research upgraded Rexahn Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a report on Wednesday, October 4th. HC Wainwright reiterated a “buy” rating and set a $19.50 price objective on shares of Rexahn Pharmaceuticals in a report on Monday, November 6th. Finally, ValuEngine upgraded Rexahn Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, November 2nd.
Shares of Rexahn Pharmaceuticals (RNN) opened at $2.12 on Friday. Rexahn Pharmaceuticals has a twelve month low of $0.38 and a twelve month high of $7.10. The company has a market capitalization of $67.24, a price-to-earnings ratio of -2.28 and a beta of -0.66.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in RNN. Susquehanna International Group LLP acquired a new position in shares of Rexahn Pharmaceuticals in the 2nd quarter valued at $2,905,000. Sabby Management LLC acquired a new stake in Rexahn Pharmaceuticals during the 2nd quarter worth about $706,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Rexahn Pharmaceuticals during the 3rd quarter worth about $119,000.
About Rexahn Pharmaceuticals
Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.
Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.